Bioadherent oral rinse gel for effective relief of pain associated with oral mucositis

Gelclair is a bioadherent oral rinse gel which provides effective pain relief by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (which may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures. Gelclair is also indicated for diffuse aphthous ulcers.

  • By creating a protective film that counteracts the overstimulation of nerve endings Gelclair provides pain relief 1
  • Gelclair improves the ability to eat and drink by reducing pain 2, 4

Gelclair is a concentrated oral rinse gel, classified as a medical device. It contains three main ingredients.

  • Polyvinylpyrrolidone (PVP) – A polymer characterized by mucoadhesive and film forming properties that boost the action of sodium hyaluronate.
  • Glycyrrhetinic Acid – The breakdown product of the active component of licorice, used as a flavoring agent.
  • Hyaluronic Acid (sodium hyaluronate) – A natural polysaccharide with anti-inflammatory and wound healing properties.  In the formulation of Gelclair, it acts as a mucoadhesive substance, able to form a film on the mucosal surface.

Gelclair has an optimal pH between 5.5 and 6.5, very similar to the physiological pH of saliva.

  • No adverse effects have been reported in clinical trials with the use of Gelclair.
  • Postmarketing reports have included infrequent complaints of burning sensation in the mouth.
  • There are no known interactions with medicinal or other products.
  • Gelclair does not contain alcohol.
  • As of 6/2017 no cases of overdose had been reported.
  • If Gelclair is swallowed accidently, no adverse effects are anticipated.
  • The administration of Gelclair is contraindicated in any patient with a known or suspected hypersensitivity to any of its ingredients.


  1. Lindsay et al, Australian nursing Journal April 2009(16); 9: 30-33.
  2. D’Andrea et al, Annals Oncol 2003; 14(supp4): 97(abstract N2).
  3. De Cordi D et al, Conegliano, October 10-12, 2001.